Novonesis targets supplement market to support GLP-1 users
NVO Novo Nordisk ADR
$40.70 -1.64%
View chart & analysis → - 1The Novonesis CEO stated that supplements can play a complementary role in obesity management and long-term health maintenance.
- 240% of adult GLP-1 users in the UK reported increased spending on vitamins and supplements.
- 3The global dietary supplement market is estimated to be valued at $209.5 billion in 2025.
So what's the key point?
Novonesis is entering the nutritional supplement market for people using obesity treatments. With 40% of UK users spending more on supplements, the market size is expected to grow.
Source CNBC · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.